Mivacurium is a non-depolarizing, reversible neuromuscular junction blocker. Mivacurium acts as an anesthetic, inhibiting pre-synaptic nicotinic acetylcholine receptors (nAChRs) in neurons and muscle. Mivacurium exhibits a rapid onset and short duration of action. This compound also displays anti-fibrillatory/anti-arrhythmic activity, as its inhibition of signaling in the parasympathetic nervous system prevents atrial fibrillation in animal models.
| Cas No. | 106861-44-3 |
|---|---|
| Purity | ≥98% |
| Formula | C58H80N2O14Cl2 |
| Formula Wt. | 1100.18 |
| IUPAC Name | bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl](E)-oct-4-enedioate;dichloride |
| Appearance | White crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M3584 Info Sheet PDF |
|---|
Patterson E, Lu Z, Lin J, et al. Antifibrillatory properties of mivacurium in a canine model of atrial fibrillation. J Cardiovasc Pharmacol. 2008 Mar;51(3):293-303. PMID: 18356695.
Jonsson M, Gurley D, Dabrowski M, et al. Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology. 2006 Sep;105(3):521-33. PMID: 16931985.
Feldman SA, Wu X, England A. Rate of 'onset' and 'offset' of four non-depolarising neuromuscular blocking drugs. Anaesthesia. 1995 Jun;50(6):510-3. PMID: 7618664.
